Neurology is one of the branches of medicine that can benefit the most from a thorough understanding of cannabinoids affecting the human body. The endocannabinoid system (ECS) in the body was discovered in 1988 during research into the medical effects of cannabis. Ever since, neurology researchers have turned their attention to cannabis in an attempt to learn more. They want to learn how the multiple strains and varieties of cannabis affect the different receptors of the ECS and how they may one day be used to treat neurodegenerative diseases..

Cannabis and CBD oil could one day prove to be effective in treating nerve pain, epilepsy, Parkinson’s disease, Alzheimer’s, seizure disorders, and neurodegenerative diseases. Expanding the types of illnesses and diseases that are connected to the ECS, cannabis and CBD oil may one day help in stroke recovery, provide relief for restless leg syndrome, or alleviate symptoms of dystonia or glaucoma.

Neurology researchers know that the ECS is involved in many neurological disorders and diseases. When the ECS was discovered, it was a single receptor that responded to the effects of cannabinoids that led them to the discovery. By continuing to research the connection between the ECS and the many cannabinoids in the multiple strains and varieties of cannabis, researchers are hoping to find effective treatments for many neurological disorders.

One reason for this degree of hope is because medical-grade cannabis contains very similar chemicals in its cannabinoids to the ones found in the body that are responsible for movement, pain, memory, appetite, and other functions. It’s thought the similarity may lead to a new discovery or the similarities might lead to the restoration of a neurological link that’s been destroyed by a neurodegenerative disease like Parkinson’s or ALS.

One of the most promising studies involved treating patients displaying muscular dystrophy symptoms with cannabis. There have been several of these large, randomized trials performed, often under double-blind conditions. These European trials administered THC and CBD and demonstrated encouraging results in the level of spasticity and reduced pain, without noticeable changes in the patient’s disability.

Although neurologists are still cautious, there are enough similarities between the chemical makeup of the ECS in humans and the cannabinoids in the many strains of cannabis to encourage more studies to be conducted worldwide.

KANA Wellness Clinic can provide more information on using cannabis and CBD oil for the reflief of neurological disorders.

“Reduced pain,
without noticeable changes
in the patient’s disability. ”